$11.36
2.90%
Nasdaq, Sep 17, 04:00 pm EDT. Closed.
ISIN
US08205P1003
Symbol
BNTC

Benitec Biopharma Inc Stock price

$11.36
-1.71 13.08% 1M
-0.39 3.32% 6M
-2.11 15.66% YTD
-2.34 17.08% 1Y
+8.45 290.38% 3Y
-57.83 83.58% 5Y
-251.67 95.68% 10Y
-198.64 94.59% 20Y
Nasdaq, Closing price Thu, Sep 17 2026
+0.32 2.90%
ISIN
US08205P1003
Symbol
BNTC
Industry

Is Benitec Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$385.1m
Enterprise Value
$290.6m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.1
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-53.9m
EBIT
$-53.9m
Net Income
$-48.9m
Free Cash Flow
$-19.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-79.7%
EBIT
-79.0%
Net Income
-80.3%
Free Cash Flow
-6.1%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-57.4%
ROIC
-
Debt/Equity
-
More
EPS
$-1.0
FCF per Share
$-0.8
Short interest
11.4%
Employees
19
Rev per Employee
$0.0

Benitec Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Benitec Biopharma Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Benitec Biopharma Inc forecast:

Buy
92%
Hold
8%

Benitec Biopharma Inc Events

Upcoming Event
SEP
21
Q4 2026 Earnings Call
in 4 days
View Past Earnings Reaction

Financial data from Benitec Biopharma Inc

Mar '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 36 36
150% 150%
-
- Research and Development Expense 30 30
91% 91%
-
-54 -54
80% 80%
-
- Depreciation and Amortization 0.06 0.06
57% 57%
-
EBIT (Operating Income) EBIT -54 -54
79% 79%
-
Net Profit -49 -49
80% 80%
-

In millions USD.

Don't miss a Thing! We will send you all news about Benitec Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Benitec Biopharma Inc Stock News

Neutral
GlobeNewsWire
3 days ago
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in October Additional inter...
Neutral
GlobeNewsWire
4 months ago
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating dis...
Neutral
GlobeNewsWire
5 months ago
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient - BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients d...

Company Profile

Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA.

Head office United States
CEO Dr. Banks
Employees 19
Founded 2019
Website benitec.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today